U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Go back to U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection| Gilead Sciences (NASDAQ: GILD) | Delayed: 150.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.56 | 52 Week High | $108.63 | |||
| Open | $150.56 | 52 Week Low | $71.39 | |||
| Day High | $150.56 | P/E | 83.18 | |||
| Day Low | $150.56 | EPS | $1.81 | |||
| Volume | 2,497 | |||||
